We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+0.42%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$499M
Cap. Flow
+$505M
Cap. Flow %
26.59%
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$130M
2
FOLD
Amicus Therapeutics
FOLD
+$49.2M
3
ALC icon
Alcon
ALC
+$47.1M
4
RVMD icon
Revolution Medicines
RVMD
+$46.1M
5
EXAS
Exact Sciences
EXAS
+$35.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$82M
2
URGN icon
UroGen Pharma
URGN
+$23.8M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M
4
LQDA icon
Liquidia Corp
LQDA
+$18.1M
5
ESTA icon
Establishment Labs
ESTA
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
51
Travere Therapeutics
TVTX
$6.05B
$5.25M 0.28%
+355,000
New +$5.88M
ELVN icon
52
Enliven Therapeutics
ELVN
$4.37B
$5.01M 0.26%
+250,000
New +$4.73M
VYGR icon
53
Voyager Therapeutics
VYGR
$189M
$4.59M 0.24%
1,475,000
+225,582
+18% +$728K
ZBH icon
54
Zimmer Biomet
ZBH
$18.8B
$4.56M 0.24%
+50,000
New +$4.83M
BDX icon
55
Becton Dickinson
BDX
$49.4B
$4.31M 0.23%
+25,000
New +$4.58M
VTYX
56
DELISTED
Ventyx Biosciences
VTYX
$4.28M 0.23%
2,000,000
– –
LNTH icon
57
Lantheus
LNTH
$6.61B
$4.09M 0.22%
+50,000
New +$4.39M
NBIX icon
58
Neurocrine Biosciences
NBIX
$16.4B
$3.77M 0.2%
+30,000
New +$3.44M
APLT
59
DELISTED
Applied Therapeutics
APLT
$3.58M 0.19%
11,500,000
– –
FATE icon
60
Fate Therapeutics
FATE
$291M
$2.82M 0.15%
2,515,000
-850
-0% -$988
PASG icon
61
Passage Bio
PASG
$14.3M
$2.44M 0.13%
305,000
– –
ANRO icon
62
Alto Neuroscience
ANRO
$1.12B
$2.09M 0.11%
950,000
+35,000
+4% +$83.3K
STRO icon
63
Sutro Biopharma
STRO
$414M
$1.86M 0.1%
260,000
– –
OKUR
64
OnKure Therapeutics
OKUR
$163M
$1.52M 0.08%
635,000
– –
VRDN icon
65
Viridian Therapeutics
VRDN
$2.46B
$1.4M 0.07%
+100,000
New +$1.36M
ALEC icon
66
Alector
ALEC
$170M
$1.37M 0.07%
976,992
+472,452
+94% +$591K
ENGN icon
67
enGene Therapeutics
ENGN
$120M
$1.35M 0.07%
370,000
– –
ARQT icon
68
Arcutis Biotherapeutics
ARQT
$3.37B
$1.33M 0.07%
+95,000
New +$1.33M
ATRA icon
69
Atara Biotherapeutics
ATRA
$74.1M
$726K 0.04%
94,085
– –
MGNX icon
70
MacroGenics
MGNX
$249M
$339K 0.02%
280,000
– –
TENX icon
71
Tenax Therapeutics
TENX
$503M
$308K 0.02%
53,439
– –
TRAW icon
72
Traws Pharma
TRAW
$8.36M
$222K 0.01%
149,800
-25,200
-14% -$40.1K
ARCT icon
73
Arcturus Therapeutics
ARCT
$175M
– –
-211,790
Closed -$2.24M
CNTA
74
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-14,888
Closed -$214K
ESTA icon
75
Establishment Labs
ESTA
$2.58B
– –
-433,193
Closed -$17.7M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Vestal Point Capital held 85 positions worth $1.9B, up 36% from $1.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Vestal Point Capital deployed $505M of net new capital in Q2 2025, opening 22 new positions and adding to 26 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $14.7M trimmed.

  • Vestal Point Capital's largest Q2 2025 buy was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.
  • Vestal Point Capital added most to Amicus Therapeutics in Q2 2025, an estimated $49.2M increase.
  • Vestal Point Capital's biggest Q2 2025 reduction was uniQure, cutting an estimated $14.7M.
  • Vestal Point Capital fully exited Insmed in Q2 2025, selling an estimated $82M.
  • Vestal Point Capital's ten largest holdings make up 45% of its $1.9B portfolio in Q2 2025.
  • Vestal Point Capital opened 22 new positions and closed 13 in Q2 2025.
  • Vestal Point Capital's portfolio value rose 36% quarter-over-quarter to $1.9B.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.